Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $45 at Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts HRMY Hot Sheet
Price: $38.08 -1.75%
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 16
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 16
Join SI Premium – FREE
Needham analyst Ami Fadia raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $45.00 (from $44.00) while maintaining a Buy rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Tempus AI Inc (TEM) PT Raised to $89 at Needham
- US Lime and Minerals (USLM) PT Lowered to $131 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
